Status:
COMPLETED
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
Lead Sponsor:
Genentech, Inc.
Conditions:
Psoriasis
Eligibility:
All Genders
Brief Summary
This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Have ever had a physician's diagnosis of chronic moderate to severe plaque psoriasis and be a candidate for treatment with Raptiva
- Are being treated with or initiating Raptiva therapy at the time of enrollment
- Be able to provide written informed consent
- Be willing and able to fully to participate for the duration of patient follow-up (5 years)
- Exclusion Criterion:
- Have previously received at least one dose of Raptiva and are not currently using or restarting treatment with Raptiva at the time of enrollment
Exclusion
Key Trial Info
Start Date :
March 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
1846 Patients enrolled
Trial Details
Trial ID
NCT00096928
Start Date
March 1 2005
End Date
October 1 2009
Last Update
July 2 2015
Active Locations (182)
Enter a location and click search to find clinical trials sorted by distance.
1
Total Skin and Beauty Dermatology Center
Birmingham, Alabama, United States, 35205
2
Deep South Dermatology
Daphne, Alabama, United States, 36526
3
The Dermatology Center
Gadsden, Alabama, United States, 35901
4
Medical Affiliated Research Center, Inc.
Huntsville, Alabama, United States, 35801